FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1698005376> ?p ?o ?g. }

• W1698005376 endingPage "669" @default.
• W1698005376 startingPage "663" @default.
• W1698005376 abstract "Study Objective Although data from the Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism ( RECORD ) 1–4 trials have shown a similar postoperative bleeding risk between rivaroxban and enoxaparin in patients undergoing total hip arthroplasty ( THA ) and total knee arthroplasty ( TKA ), anecdotal observations from local institutions have suggested that postoperative bleeding rates seemed higher in patients who received rivaroxaban than those reported in the RECORD trials. Thus, the objective of this pilot study was to assess postoperative bleeding events observed in clinical practice in patients receiving rivaroxaban after undergoing THA and TKA and to compare their results with those published in the RECORD trials. Design Retrospective cohort study with a comparator group of patients from the RECORD 1–4 trials. Setting Two institutions within a regional health care system. Patients Four hundred forty adults who received at least one dose of rivaroxaban 10 mg daily after undergoing THA or TKA in the two institutions between August 2011 and October 2013 (cohort group), and 6183 patients who received rivaroxaban in the RECORD 1–4 trials (comparator group). Measurements and Main Results Postoperative bleeding was assessed in the cohort patients versus the patients in the RECORD trials. The primary outcome, occurrence of any postoperative bleeding, was a composite of major and clinically relevant nonmajor bleeding as defined in the RECORD trials. Any postoperative bleeding occurred in 6.8% of the cohort patients versus 3.2% of the RECORD trial patients (p<0.0001); 1.4% of the cohort patients versus 0.38% of the RECORD trial patients suffered a major bleed (p=0.013). Within defined major bleeding, bleeding leading to reoperation and clinically overt extrasurgical site bleeding resulting in either a hemoglobin level decrease of at least 2 g/dl or transfusion of 2 units or greater of packed red blood cells were reported in 0.68% versus 0.19% (p=0.073) and 0.68% versus 0.13% (p=0.032), respectively, of the cohort patients versus the RECORD trial patients. Conclusion Overall, any postoperative bleeding in the cohort patients occurred significantly more frequently than that observed in the RECORD trial patients. The major bleeding rate was also significantly higher in the cohort patients, influenced by higher rates of bleeding leading to reoperation and clinically overt extrasurgical site bleeding resulting in either a hemoglobin decrease of at least 2 g/dl or transfusion of two units or greater of packed red blood cells. These findings from our pilot study are thought provoking and, thus, invite further investigation." @default.
• W1698005376 created "2016-06-24" @default.
• W1698005376 creator A5008767350 @default.
• W1698005376 creator A5021022161 @default.
• W1698005376 creator A5029837249 @default.
• W1698005376 creator A5046841882 @default.
• W1698005376 creator A5050949902 @default.
• W1698005376 creator A5058159352 @default.
• W1698005376 creator A5075671028 @default.
• W1698005376 date "2015-06-19" @default.
• W1698005376 modified "2023-10-16" @default.
• W1698005376 title "Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data" @default.
• W1698005376 cites W1839975480 @default.
• W1698005376 cites W1965492206 @default.
• W1698005376 cites W2013750247 @default.
• W1698005376 cites W2014491911 @default.
• W1698005376 cites W2022932023 @default.
• W1698005376 cites W2027200715 @default.
• W1698005376 cites W2028162842 @default.
• W1698005376 cites W2036506340 @default.
• W1698005376 cites W2046030429 @default.
• W1698005376 cites W2057843847 @default.
• W1698005376 cites W2060578439 @default.
• W1698005376 cites W2106407512 @default.
• W1698005376 cites W2118753095 @default.
• W1698005376 cites W2136098489 @default.
• W1698005376 cites W2150567120 @default.
• W1698005376 cites W2150988584 @default.
• W1698005376 cites W2151252098 @default.
• W1698005376 cites W3016782834 @default.
• W1698005376 doi "https://doi.org/10.1002/phar.1608" @default.
• W1698005376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26095331" @default.
• W1698005376 hasPublicationYear "2015" @default.
• W1698005376 type Work @default.
• W1698005376 sameAs 1698005376 @default.
• W1698005376 citedByCount "10" @default.
• W1698005376 countsByYear W16980053762016 @default.
• W1698005376 countsByYear W16980053762017 @default.
• W1698005376 countsByYear W16980053762018 @default.
• W1698005376 countsByYear W16980053762019 @default.
• W1698005376 countsByYear W16980053762020 @default.
• W1698005376 countsByYear W16980053762021 @default.
• W1698005376 countsByYear W16980053762023 @default.
• W1698005376 crossrefType "journal-article" @default.
• W1698005376 hasAuthorship W1698005376A5008767350 @default.
• W1698005376 hasAuthorship W1698005376A5021022161 @default.
• W1698005376 hasAuthorship W1698005376A5029837249 @default.
• W1698005376 hasAuthorship W1698005376A5046841882 @default.
• W1698005376 hasAuthorship W1698005376A5050949902 @default.
• W1698005376 hasAuthorship W1698005376A5058159352 @default.
• W1698005376 hasAuthorship W1698005376A5075671028 @default.
• W1698005376 hasConcept C126322002 @default.
• W1698005376 hasConcept C141071460 @default.
• W1698005376 hasConcept C167135981 @default.
• W1698005376 hasConcept C168563851 @default.
• W1698005376 hasConcept C195910791 @default.
• W1698005376 hasConcept C201903717 @default.
• W1698005376 hasConcept C2776265017 @default.
• W1698005376 hasConcept C2776301958 @default.
• W1698005376 hasConcept C2778336525 @default.
• W1698005376 hasConcept C2778661090 @default.
• W1698005376 hasConcept C2779161974 @default.
• W1698005376 hasConcept C2780011451 @default.
• W1698005376 hasConcept C2780868729 @default.
• W1698005376 hasConcept C535046627 @default.
• W1698005376 hasConcept C68312169 @default.
• W1698005376 hasConcept C71924100 @default.
• W1698005376 hasConcept C72563966 @default.
• W1698005376 hasConceptScore W1698005376C126322002 @default.
• W1698005376 hasConceptScore W1698005376C141071460 @default.
• W1698005376 hasConceptScore W1698005376C167135981 @default.
• W1698005376 hasConceptScore W1698005376C168563851 @default.
• W1698005376 hasConceptScore W1698005376C195910791 @default.
• W1698005376 hasConceptScore W1698005376C201903717 @default.
• W1698005376 hasConceptScore W1698005376C2776265017 @default.
• W1698005376 hasConceptScore W1698005376C2776301958 @default.
• W1698005376 hasConceptScore W1698005376C2778336525 @default.
• W1698005376 hasConceptScore W1698005376C2778661090 @default.
• W1698005376 hasConceptScore W1698005376C2779161974 @default.
• W1698005376 hasConceptScore W1698005376C2780011451 @default.
• W1698005376 hasConceptScore W1698005376C2780868729 @default.
• W1698005376 hasConceptScore W1698005376C535046627 @default.
• W1698005376 hasConceptScore W1698005376C68312169 @default.
• W1698005376 hasConceptScore W1698005376C71924100 @default.
• W1698005376 hasConceptScore W1698005376C72563966 @default.
• W1698005376 hasIssue "7" @default.
• W1698005376 hasLocation W16980053761 @default.
• W1698005376 hasLocation W16980053762 @default.
• W1698005376 hasOpenAccess W1698005376 @default.
• W1698005376 hasPrimaryLocation W16980053761 @default.
• W1698005376 hasRelatedWork W2036007875 @default.
• W1698005376 hasRelatedWork W2062272588 @default.
• W1698005376 hasRelatedWork W2148056324 @default.
• W1698005376 hasRelatedWork W2174581859 @default.
• W1698005376 hasRelatedWork W2197337485 @default.
• W1698005376 hasRelatedWork W2379972596 @default.
• W1698005376 hasRelatedWork W2411696557 @default.
• W1698005376 hasRelatedWork W3146056168 @default.

• next